T. Rowe Price Investment Management, Inc. filed Amendment No. 2 to a Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of 5,885,888 shares of Dianthus Therapeutics Inc. common stock as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: T. Rowe Price Investment Management, Inc. reported beneficial ownership of 5,885,888 shares of Dianthus Therapeutics Inc. common stock.
  • Percent of class: The reported stake represents 10.5% of the class of securities, according to the filing.
  • Sole voting power: The filing discloses sole voting power over 5,753,835 shares, with no shared voting power reported.
  • Sole dispositive power: T. Rowe Price reported sole dispositive power over all 5,885,888 shares, with no shared dispositive power.
  • Event date: The date of the event requiring this filing was September 30, 2026.
  • Filer type: T. Rowe Price Investment Management, Inc. is classified as an investment adviser (type "IA") organized in Maryland.

T. Rowe Price Discloses 5,885,888 Shares in Dianthus Therapeutics as of September 30, 2026

T. Rowe Price Investment Management, Inc., a Maryland-incorporated investment adviser with a principal business address at 1307 Point Street, Baltimore, MD 21231, submitted Amendment No. 2 to Schedule 13G on November 16, 2026, covering its holdings in Dianthus Therapeutics Inc. (NASDAQ:DNTH). The filing reports a triggering event date of September 30, 2026, and covers shares of common stock identified by CUSIP number 252828108.

According to the filing, T. Rowe Price Investment Management, Inc. beneficially owns 5,885,888 shares, representing 10.5% of the class. Of that total, the firm holds sole voting power over 5,753,835 shares and sole dispositive power over the full 5,885,888 shares. No shared voting or dispositive power was reported. The filing notes that Item 5 (ownership of 5% or less) and Items 6 through 9 were each marked "Not Applicable."

The filing includes a certification by T. Rowe Price Investment Management, Inc. stating that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer." The firm further declared that "the filing of Schedule 13G shall not be construed as an admission that Price Investment Management is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied." The statement was signed by Ellen York, Vice President, on November 16, 2026.

What Was Disclosed

T. Rowe Price Investment Management, Inc. filed Amendment No. 2 to Schedule 13G disclosing beneficial ownership of 5,885,888 shares, equal to 10.5% of Dianthus Therapeutics Inc. common stock, with the event date of September 30, 2026.